<DOC>
	<DOC>NCT01499368</DOC>
	<brief_summary>To evaluate the healing rate and safety of Lafutidine in erosive esophagitis</brief_summary>
	<brief_title>A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients</brief_title>
	<detailed_description />
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Lafutidine</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Famotidine</mesh_term>
	<criteria>Patients who had symptoms of heartburn with a diagnosis of grade A to D reflux esophagitis according to the Los Angeles classification Gastric or duodenal ulcers (excluding ulcer scars) Concurrent presence of Barrett's esophagus A history of a poor response to H2RA or PPI given in the recommended dose for 8 weeks Other conditions considered by the attending physician to potentially affect the assessment of efficacy and safety</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>